TherapeuticsMD Inc Cash Flow Conversion Efficiency
TherapeuticsMD Inc cash flow conversion efficiency. Based on the latest financial reports, TherapeuticsMD Inc (TXMD) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.37 Million) by net assets ($26.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TherapeuticsMD Inc (1994–2025)
Cash flow conversion efficiency of TherapeuticsMD Inc from 1994 to 2025. This chart illustrates how TherapeuticsMD Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of TherapeuticsMD Inc for real-time trading data and today's change.
TherapeuticsMD Inc Cash Flow Conversion Ratio Explained
TherapeuticsMD Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TherapeuticsMD Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TherapeuticsMD Inc ranked by their cash flow conversion efficiency. Also see TherapeuticsMD Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zuleika Gold Ltd
AU:ZAG
|
0.144x |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
-2.410x |
|
Duckshin Housing Co. Ltd
KQ:090410
|
-0.080x |
|
Bangsaphan Barmill Public Company Limited
BK:BSBM
|
-0.040x |
|
Food and Drinks Public Company Limited
BK:F&D
|
0.004x |
|
Kintech Electronics Co Ltd
TWO:6210
|
-0.056x |
|
Sebang Co Ltd
KO:004365
|
0.031x |
|
Alla Public Company Limited
BK:ALLA
|
0.049x |
Annual Cash Flow Conversion Efficiency for TherapeuticsMD Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of TherapeuticsMD Inc from 1994 to 2025. Review TXMD FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.88 Million | $2.45 Million | 0.091x | +241.41% |
| 2024-12-31 | $27.37 Million | $732.00K | 0.027x | +101.63% |
| 2023-12-31 | $29.29 Million | $-48.14 Million | -1.644x | -1316.55% |
| 2022-12-31 | $35.14 Million | $-4.08 Million | -0.116x | -107.35% |
| 2021-12-31 | $-93.62 Million | $-147.81 Million | 1.579x | +22.77% |
| 2020-12-31 | $-124.00 Million | $-159.47 Million | 1.286x | +107.14% |
| 2019-12-31 | $9.20 Million | $-165.70 Million | -18.008x | -1544.25% |
| 2018-12-31 | $97.52 Million | $-106.81 Million | -1.095x | -86.83% |
| 2017-12-31 | $129.91 Million | $-76.16 Million | -0.586x | -8.09% |
| 2016-12-31 | $127.49 Million | $-69.14 Million | -0.542x | +56.73% |
| 2015-12-31 | $63.06 Million | $-79.04 Million | -1.253x | -33.24% |
| 2014-12-31 | $48.39 Million | $-45.52 Million | -0.941x | -147.77% |
| 2013-12-31 | $54.70 Million | $-20.77 Million | -0.380x | -104.27% |
| 2012-12-31 | $-1.43 Million | $-12.74 Million | 8.888x | +206.34% |
| 2011-12-31 | $-1.71 Million | $-4.97 Million | 2.901x | +414.65% |
| 2010-12-31 | $-907.55K | $836.83K | -0.922x | -168.72% |
| 2009-12-31 | $-311.05K | $-417.34K | 1.342x | +118.86% |
| 2008-12-31 | $18.70K | $-133.00K | -7.114x | -963.18% |
| 2007-12-31 | $417.54K | $344.10K | 0.824x | +321.58% |
| 2006-12-31 | $1.69 Million | $329.84K | 0.195x | -37.69% |
| 2005-12-31 | $1.31 Million | $412.34K | 0.314x | +58.80% |
| 2004-12-31 | $1.05 Million | $207.73K | 0.198x | +22.22% |
| 2003-12-31 | $866.11K | $140.00K | 0.162x | +18.95% |
| 2002-12-31 | $736.41K | $100.08K | 0.136x | -43.60% |
| 2001-12-31 | $672.09K | $161.95K | 0.241x | +10.07% |
| 2000-12-31 | $611.97K | $133.97K | 0.219x | +116.68% |
| 1999-12-31 | $480.35K | $48.53K | 0.101x | +3.79% |
| 1998-12-31 | $458.12K | $44.60K | 0.097x | -37.48% |
| 1997-12-31 | $497.89K | $77.53K | 0.156x | +35.32% |
| 1996-12-31 | $510.88K | $58.78K | 0.115x | -20.11% |
| 1995-12-31 | $440.53K | $63.45K | 0.144x | -17.20% |
| 1994-12-31 | $418.86K | $72.86K | 0.174x | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more